[go: up one dir, main page]

WO2004042085A3 - Methode de quantification d'un rapport entre au moins deux sequences d'acides nucleiques - Google Patents

Methode de quantification d'un rapport entre au moins deux sequences d'acides nucleiques Download PDF

Info

Publication number
WO2004042085A3
WO2004042085A3 PCT/NL2003/000780 NL0300780W WO2004042085A3 WO 2004042085 A3 WO2004042085 A3 WO 2004042085A3 NL 0300780 W NL0300780 W NL 0300780W WO 2004042085 A3 WO2004042085 A3 WO 2004042085A3
Authority
WO
WIPO (PCT)
Prior art keywords
interest
nucleic acids
determining
nucleic acid
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2003/000780
Other languages
English (en)
Other versions
WO2004042085A2 (fr
Inventor
Eveline Catherina A Timmermans
Gemen Bob Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Primagen Holding BV
Original Assignee
Primagen Holding BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02079673A external-priority patent/EP1418241A1/fr
Application filed by Primagen Holding BV filed Critical Primagen Holding BV
Priority to NZ540144A priority Critical patent/NZ540144A/en
Priority to JP2004549721A priority patent/JP2006505268A/ja
Priority to AU2003279621A priority patent/AU2003279621A1/en
Publication of WO2004042085A2 publication Critical patent/WO2004042085A2/fr
Publication of WO2004042085A3 publication Critical patent/WO2004042085A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode de quantification d'un rapport initial de quantité d'au moins deux acides nucléiques d'intérêt dans un échantillon au moyen d'une réaction d'amplification des acides nucléiques multiplex, consistant:- à amplifier lesdits acides nucléiques d'intérêt dans ladite réaction d'amplification; - à mesurer la quantité d'au moins deux acides nucléiques d'intérêt dans au moins deux repères temporels différents de ladite réaction; - à déterminer à partir d'au moins deux desdites mesures le taux d'amplification desdits acides nucléiques d'intérêt; - à comparer lesdits taux à une référence; et - à déterminer à partir de ladite comparaison ledit rapport initial de quantité desdits acides nucléiques d'intérêt dans ledit échantillon. Au moins un facteur variable de ladite réaction d'amplification d'acides nucléiques est, de préférence, ajusté afin d'atteindre des niveaux détectables de tous les acides nucléiques d'intérêt avant d'atteindre une limite d'amplification et/ou de détection d'un ou de plusieurs acides nucléiques d'intérêt. La méthode de l'invention permet de déterminer de petites différences entre les rapports. Une mesure directe du rapport initial des acides nucléiques peut, de plus, être déterminée. La méthode de l'invention est, par exemple, adaptée pour déterminer le fonctionnement d'un organisme cellulaire, pour déterminer la stadification d'une maladie, et pour déterminer l'activité thérapeutique et/ou les éventuels effets secondaires d'un médicament ou d'un composé candidat.
PCT/NL2003/000780 2002-11-08 2003-11-07 Methode de quantification d'un rapport entre au moins deux sequences d'acides nucleiques Ceased WO2004042085A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
NZ540144A NZ540144A (en) 2002-11-08 2003-11-07 Method for quantifying a ratio between at least two nucleic acid sequences
JP2004549721A JP2006505268A (ja) 2002-11-08 2003-11-07 少なくとも２つの核酸配列間の比率を定量化する方法
AU2003279621A AU2003279621A1 (en) 2002-11-08 2003-11-07 Method for quantifying a ratio between at least two nucleic acid sequences

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42505502P 2002-11-08 2002-11-08
EP02079673.6 2002-11-08
US60/425,055 2002-11-08
EP02079673A EP1418241A1 (fr) 2002-11-08 2002-11-08 Procédé de quantifier le rapport de deux séquences d'acides nucléiques

Publications (2)

Publication Number Publication Date
WO2004042085A2 WO2004042085A2 (fr) 2004-05-21
WO2004042085A3 true WO2004042085A3 (fr) 2004-08-05

Family

ID=32313842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2003/000780 Ceased WO2004042085A2 (fr) 2002-11-08 2003-11-07 Methode de quantification d'un rapport entre au moins deux sequences d'acides nucleiques

Country Status (6)

Country Link
JP (1) JP2006505268A (fr)
KR (1) KR20050088998A (fr)
AU (1) AU2003279621A1 (fr)
CA (1) CA2448769A1 (fr)
NZ (1) NZ540144A (fr)
WO (1) WO2004042085A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2565481T3 (es) * 2005-03-24 2016-04-05 Thrombogenics N.V. Anticuerpo anti-PlGF novedoso
KR101414714B1 (ko) * 2007-11-20 2014-07-03 삼성전자주식회사 경쟁적 증폭 반응을 이용하여 표적 핵산을 검출하는 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046470A2 (fr) * 2000-12-04 2002-06-13 Primagen Holding B.V. Analyse d'organites cellulaires endosymbiontes et composes pouvant etre identifies par cette analyse

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046470A2 (fr) * 2000-12-04 2002-06-13 Primagen Holding B.V. Analyse d'organites cellulaires endosymbiontes et composes pouvant etre identifies par cette analyse

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAAR DE M P ET AL: "ONE-TUBE REAL-TIME ISOTHERMAL AMPLIFICATION ASSAY TO IDENTIFY AND DISTINGUISH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPES A,B, AND C AND CIRCULATING RECOMBINANT FORMS AE AND AG", JOURNAL OF CLINICAL MICROBIOLOGY, WASHINGTON, DC, US, vol. 39, no. 5, May 2001 (2001-05-01), pages 1895 - 1902, XP001011572, ISSN: 0095-1137 *
CRAWFORD ERIN L ET AL: "Multiplex standardized RT-PCR for expression analysis of many genes in small samples.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 26 APR 2002, vol. 293, no. 1, 26 April 2002 (2002-04-26), pages 509 - 516, XP002249374, ISSN: 0006-291X *
MEIJERINK J ET AL: "A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR.", THE JOURNAL OF MOLECULAR DIAGNOSTICS: JMD. UNITED STATES MAY 2001, vol. 3, no. 2, May 2001 (2001-05-01), pages 55 - 61, XP002249372, ISSN: 1525-1578 *
MOUTOU CÉLINE ET AL: "Multiplex PCR combining deltaF508 mutation and intragenic microsatellites of the CFTR gene for pre-implantation genetic diagnosis (PGD) of cystic fibrosis.", EUROPEAN JOURNAL OF HUMAN GENETICS: EJHG. ENGLAND APR 2002, vol. 10, no. 4, April 2002 (2002-04-01), pages 231 - 238, XP002249373, ISSN: 1018-4813 *
VAN DEURSEN P B ET AL: "A novel quantitative multiplex NASBA method: application to measuring tissue factor and CD14 mRNA levels in human monocytes.", NUCLEIC ACIDS RESEARCH. ENGLAND 1 SEP 1999, vol. 27, no. 17, 1 September 1999 (1999-09-01), pages e15, XP002249371, ISSN: 1362-4962 *

Also Published As

Publication number Publication date
AU2003279621A1 (en) 2004-06-07
CA2448769A1 (fr) 2004-05-08
WO2004042085A2 (fr) 2004-05-21
KR20050088998A (ko) 2005-09-07
NZ540144A (en) 2008-08-29
JP2006505268A (ja) 2006-02-16

Similar Documents

Publication Publication Date Title
Fell et al. Evaluation of the Accusport® lactate analyser
Soetaer et al. Dynamic response of deep‐sea sediments to seasonal variations: A model
WO2004063713A3 (fr) Determination non invasive de direction et de vitesse de modification d'un analyte
WO2003040728A3 (fr) Instrument
ATE364842T1 (de) Invasives verfahren zur in vivo analytvermessung
Malayappan et al. Urinary analysis of 8-oxoguanine, 8-oxoguanosine, fapy-guanine and 8-oxo-2′-deoxyguanosine by high-performance liquid chromatography–electrospray tandem mass spectrometry as a measure of oxidative stress
EP1439393A3 (fr) Procédés de détection utilisants TIMP 1 pour le diagnostic du cancer du colon
WO2002027326A3 (fr) Procede et trousse pour la determination transdermique de la concentration d'une analyte dans le sang
EP1447665A3 (fr) Méthode pour la réduction d'effet de hématocrite dans la détection d'un analyte dans un échantillon de sang total, kit d'essai et article de test utilisable dans cette méthode
WO2001061033A3 (fr) Amplification de sonde multiplex pouvant etre ligaturee
WO2005052728A3 (fr) Procede et systeme permettant de determiner un niveau d'activite chez un individu
WO2007115694A3 (fr) Biocapteur miniaturise avec detection amperometrique optimisee
WO2005023091A3 (fr) Procede de diagnostic prenatal non effractif
WO2005095644A3 (fr) Procede d'identification de signatures dans des profils d'expression genetique complexes
EP1427810A4 (fr) Methode et essai de quantification permettant d'evaluer l'etat du systeme c-kit/scf/pakt
WO2005038039A3 (fr) Procede et kit pour l'amplification multiplex par amorces d'acides nucleiques
WO2003009100A3 (fr) Methodes, appareil et programmes informatiques de verification de l'integrite d'une sonde
WO2003093788A3 (fr) Bande d'essai et procede permettant de determiner la concentration de creatinine dans un fluide corporel
WO2007070621A3 (fr) Indicateurs de pronostic pour des tumeurs solides humaines
WO2000070340A3 (fr) Materiaux et procedes se rapportant au diagnostic de maladie
CA2289043A1 (fr) Procede de detection ou de prevision de maladies ischemiques
Slowiaczek et al. The determination of purine levels in human and mouse plasma
WO2005085292A3 (fr) Procede de detection de la forme libre activable du psa et son utilisation pour le diagnostic des pathologies benignes de la prostate et de l'adenocarcinome de la prostate
WO2004042085A3 (fr) Methode de quantification d'un rapport entre au moins deux sequences d'acides nucleiques
WO2003100079A3 (fr) Procede d'analyse de formes proenzymatiques d'antigenes specifiques de la prostate dans des serums pour ameliorer la detection du cancer de la prostate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 168466

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020057008235

Country of ref document: KR

Ref document number: 2004549721

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003279621

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 540144

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 20038A8470X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057008235

Country of ref document: KR

122 Ep: pct application non-entry in european phase